Available EXPANDED_ACCESS NCT06797362

Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors

Expanded Access Treatment of Zidesamtinib (NVL-520) in Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors

Sponsor: Nuvalent Inc.

Conditions Non Small Cell Lung Cancer ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

Interventions NVL-520

Updated 9 times since 2025 Last updated: Feb 12, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Non Small Cell Lung Cancer and ROS1-positive Non-Small Cell Lung Cancer (NSCLC), this trial is ongoing. The trial is conducted by Nuvalent Inc. and has accumulated 9 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Feb 2026 — Present [monthly]

Available
Jan 2026 — Feb 2026 [monthly]

Available
Dec 2025 — Jan 2026 [monthly]

Available
Oct 2025 — Dec 2025 [monthly]

Available
Sep 2025 — Oct 2025 [monthly]

Available

▶ Show 4 earlier versions

Jul 2025 — Sep 2025 [monthly]

Available
Jun 2025 — Jul 2025 [monthly]

Available
May 2025 — Jun 2025 [monthly]

Available
Feb 2025 — May 2025 [monthly]

Available

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nuvalent Inc.

Data source: Nuvalent Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Aurora, United States , Barcelona, Spain , Bari, Italy , Boston, United States , Camperdown, Australia , Chicago, United States , Edmonton, Canada , Groningen, Netherlands , London, United Kingdom and 19 more locations